Loading...
OTCM
PKTX
Market cap3mUSD
Jun 09, Last price  
0.01USD
1D
-4.29%
1Q
-28.10%
Jan 2017
-83.89%
IPO
-99.42%
Name

ProtoKinetix Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.92%
Rev. gr., 5y
%
Revenues
0k
2,0000000000000000000000
Net income
0k
P
-5,096,296-1,967,633-2,728,269-1,550,818-1,270,109-1,388,772-1,231,933-197,118-448,577-168,479-1,254,793-1,524,638-1,513,634-1,216,343-4,197,897-7,644,490-2,329,310-1,907,309-415,4790
CFO
-223k
L-40.68%
-585,780-380,456-645,265-439,448-219,428-114,876-396,635-149,871-105,341-229,248-574,235-820,253-605,109-453,493-850,658-881,308-889,891-804,669-375,989-223,050
Earnings
Jul 28, 2025

Profile

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
URL
https://www.protokinetix.com/
IPO date
Jan 07, 2002
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
306
415
1,907
Unusual Expense (Income)
NOPBT
(306)
(415)
(1,907)
NOPBT Margin
Operating Taxes
1
Tax Rate
NOPAT
(306)
(415)
(1,907)
Net income
(415)
-78.22%
(1,907)
-18.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
256
430
905
BB yield
-7.14%
-6.79%
-11.06%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
5
(20)
(26)
Cash flow
Cash from operating activities
(223)
(376)
(805)
CAPEX
(59)
(132)
Cash from investing activities
(58)
(59)
(132)
Cash from financing activities
256
430
905
FCF
(200)
(408)
(1,902)
Balance
Cash
(5)
20
26
Long term investments
Excess cash
20
26
Stockholders' equity
(48,226)
(47,862)
(47,447)
Invested Capital
48,568
48,298
47,868
ROIC
ROCE
EV
Common stock shares outstanding
358,558
333,103
307,392
Price
0.01
-47.37%
0.02
-28.57%
0.03
-73.40%
Market cap
3,586
-43.35%
6,329
-22.60%
8,177
-71.98%
EV
3,590
6,309
8,151
EBITDA
(253)
(367)
(1,849)
EV/EBITDA
Interest
Interest/NOPBT